June 13 (Reuters) – Johnson & Johnson: * NEW TALVEY® (TALQUETAMAB-TGVS) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) DATA DEMONSTRATE THE STRENGTH OF A BISPECIFIC COMBINATION IN
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Spotify forecasts profit and monthly active users below estimates, shares fall
Aug 4 (Reuters) - Spotify forecast third-quarter profit and monthly active users below Wall Street…
McDonald's US sales growth slows as value deals fail to draw enough diners
By Savyata Mishra Aug 4 (Reuters) - McDonald's on Tuesday missed U.S. sales growth expectations…
Nohit Arora Honoured for Advancing Enterprise AI and Product Strategy
Product leader Nohit Arora, with 12+ years of experience in AI-enabled and data-driven enterprise products,…
